News | May 08, 2026
Roche moves to acquire PathAI for up to $1.05 billion in major AI pathology push
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Former DCGI and now advisor to UP CM highlights medical device growth, healthcare expansion, and investment opportunities in the state
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The company plans to collaborate with European medical centres to expand adoption of its robotic microsurgery platform
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Approval strengthens the company’s growing international anti-infective portfolio
Subscribe To Our Newsletter & Stay Updated
